Maxpro Capital (NASDAQ:JMAC) announced in an 8-K this morning that it has entered into a PIPE agreements adding $23.65 million to its combination with drug developer Apollomics.
Of these, $21.35 million was raised at $10 per share as “Series A preferred shares”. These will be convertible into 1.25 common shares each and will be locked up for six months. An additional $2.3 million PIPE was raised at $10 per share without these benefits, but these shares are to come with a 1/4 warrant attached that may be exercised between six months and five years out from close.
The parties originally announced their $932 million deal in September 2022. Foster City, California-based Apollomics is developing a line of drug candidates to treat rare cancers with clinical processes nearing completion in both the US and Chinese treatment markets.
In November, it received an orphan drug designation for its APL-101 drug candidate, which is in Phase II trials to potentially treat non-small cell lung cancer and other cancer types.
Maxpro has a transaction deadline coming up on April 13 and it has already used its two automatic extensions.
Launch Two (NASDAQ:LPBBU) has filed for a $200 million IPO that shows how the market has shifted for new issuance since its sister SPAC Launch One (NASDAQ:LPAAU) filed just over a month ago. Both SPACs are underwritten by Cantor Fitzgerald and seeking nominally the same raise at IPO, but Launch Two is overfunding its trust...
FTAC Emerald (NASDAQ:EMLD) has entered into a definitive agreement to combine with crypto fintech firm Fold at an enterprise value of $381 million. Phoenix, Arizona-based Fold provides digital banking services backed by a treasury of Bitcoin that includes FDIC-secured checking accounts as well Bitcoin trading and awards. The combined company is expected to trade on...
At the SPAC of Dawn Dealmakers remain confident that AI is going to play a big role in their M&A processes, but feel unprepared for some the changes, according to a new survey of 225 corporate and 75 private equity transactions professionals. SS&C subsidiary Mergermarket generated the report that found more than half of respondents...
Trailblazer Merger I (NASDAQ:TBMC) has entered into a definitive agreement to combine with data intelligence firm Cyabra at an enterprise value of $70 million. Tel Aviv-based Cyabra provides tools to corporations and governments to identify fake accounts and combat social media disinformation. The combined company is expected to trade on the Nasdaq once the deal...
Chain Bridge I (NASDAQ:CBRG) has entered into a definitive agreement to combine with cannabinoid pharmaceuticals firm Phytanix Bio at a pre-deal valuation of $58 million. Santa Barbara, California-based Phytanix is working to develop bladder and seizure treatments using cannabis-based substances. The combined company is expected to trade on the Nasdaq under the symbol “PHYX” once...